Keystone Bio
Saint Louis
About Keystone Bio
Keystone Bio has identified and is targeting a "one of a kind Inflammapath ", the keystone pathogen of chronic inflammation that’s been shown to initiate and advance Atherosclerosis, Heart disease and Alzheimer's disease. Keystone Bio is a nextgen PharmaBiome biotech that has identified and is targeting a "one of a kind Inflammapath ", the keystone pathogen of chronic inflammation that’s been shown to initiate and advance Atherosclerosis, Heart disease and Alzheimer's disease.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $5.0M
- Last round: Series Unknown (Apr 2019)
- Website: keystonebio.com
- Phone: (314) 471-9655
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/keystone-bio-53910 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.